Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor

During the company’s 2019 R&D Investor Day, Takeda highlighted the importance of gene and cell therapies as it moves forward in its continued transformation from the Shire deal, as well as other collaborations the company has forged since. However, in what might be considered a refreshing moment of real honesty, Andy Plump, Takeda’s head of R&D, recently noted that sometimes being on the cutting edge of treatments does not mean your treatment will be the top-selling preference. In an interview with the Boston Business Journal, Plump revealed that he did not believe the company’s hemophilia A gene therapy treatment would be a market leader. In fact, he went so far as to say the treatment would probably not even be a contender.